MINE Opinions 11/02/2014 08:36:10 $MINE Who said its not a

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
MINE Opinions 11/02/2014 08:36:10 $MINE
Who said its not a real company? I never said that obviously it's a real company who's affiliated with beverages.
Man, there selling a ton of these cases. Looks like a real company to me..
They are still in the Treasury until issued. This has to be done this way by Securities Law and Rules.
I don't know for sure yet where the 162 million would go because I haven't had time to DD the Avanzar Purchase Order. I expect they go there. Now, if Avanzar is prepaid as per agreement then those shares go back to Treasury proper. Can anyone say when the Preferreds will convert. Answer is no.
When the company buys back shares from the OS these numbers will stay the same, even if OS went to -0-.
Now we are up to 671M in the Treasury not issued.
Shares RESERVED Other (162,756,751)
Shares RESERVED Preferred (450,000,000)
Total Shares RESERVED (612,756,751)
Shares RESERVED Other (162,756,751)
Shares RESERVED Preferred (450,000,000)
Total Shares RESERVED (612,756,751) Active 37

Shares available to issue: 58,466,073

All of those reserved shares are allocated towards something. They are not issued, but my point is that if the company wants to fund anything additional,unless they pay off the reserved items, they only have 58 million more shares for anything further beyond their obligations. They can't use the shares which they've reserved for the preferred shares as long as the preffered shares exist, per the company bylaws. Additionally the shares reserved for the preferred shares do not currently reserve enough at the current pps since it's dropped so much.
Lol. Never a fan of the Bush's but that's funny right there. Go $MINE!
Read my lips. 612+58=670M still in the Treasury...!!! And not issued.
Yes, but they now only have 58 million left not reserved, so if they want to issue for any additional purposes, they don't have much left to do so with.
Thanks bud, appreciate the tip
I know, was a vote of confidence for you. Trade the high probable setups and I'm sure you'll make it.
Quote:
Not even close. But its obviously a long rough journey

This stuff sells, man. Everyone loves it.

Check out the amount of cases left:

https://twitter.com/jeff4liberty/status/528746745501863936
Not even close. But its obviously a long rough journey
Nice office and profile man. Sounds like you're well on your way to making it on Forbes. I wish you the best
Quote:
So don't read it! Thanks for reading up on me!

So don't read it! Thanks for reading up on me!
-Spell. com results
-Celebrity endorsement
-Distribution up dates
-retail volume

Where is the big guy , with the answers??
I cleaaaely stated in my post "OLD...."
Date of tweet: May 2014
facepalm.jpg LMMFAO old news man, old bs news hehe

Quote:
Old JIM CRAMER tweet about MINE

https://twitter.com/jimcramer/status/462363978589421569

The RESERVE OF Shares were appointed to each location from the Treasury and still part of the Treasury Stock.
That is why they call them RESERVE.
RESERVED Other (162,756,751)
Shares RESERVED Preferred (450,000,000)
Total Shares RESERVED (612,756,751)

Thanks bro. Hit my old bro up on that tweet.
Thanks Mitch
Notification That Annual Report Will Be Submitted Late (nt 10-k) "Edgar (US Regulatory)" - 10/29/2014 4:16:08 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/27/2014 1:16:47 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/3/2014 10:44:53 AM
Minerco's Level 5 Awards VitaminFIZZ® Distribution Deal "InvestorsHub NewsWire" - 8/14/2014 12:34:08 PM
Amended Current Report Filing (8-k/a) "Edgar (US Regulatory)" - 8/7/2014 6:03:29 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/6/2014 5:27:33 PM
VitaminFizz(R) Starts Full Scale Commercial Production "InvestorsHub NewsWire" - 8/4/2014 6:03:03 PM
VitaminFIZZ® Hits The Production Line in August "PR Newswire (US)" - 7/23/2014 10:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/21/2014 1:00:56 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/10/2014 9:40:32 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/10/2014 9:30:34 AM
Information Statement - All Other (definitive) (def 14c) "Edgar (US Regulatory)" - 7/8/2014 5:29:30 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/26/2014 9:30:36 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/25/2014 3:02:20 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/25/2014 3:00:37 PM
Level 5 Beverage Company Acquires the Vitamin Creamer(R) Trademark and Brand "Marketwired" - 6/25/2014 9:55:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/25/2014 9:45:40 AM
Level 5 Beverage Company Launches VitaminFIZZ(R) in the New York City Market "Marketwired" - 6/24/2014 9:40:00 AM
Proxy Statement - Other Information (preliminary) (pre 14c) "Edgar (US Regulatory)" - 6/24/2014 9:20:21 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 6/23/2014 5:09:00 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/23/2014 9:31:01 AM
Top Shelf Brands Holdings Forms Advisory Board. "PR Newswire (US)" - 6/23/2014 9:00:00 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) "Edgar (US Regulatory)" - 6/16/2014 11:59:33 AM
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading